Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

BACKGROUND: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but l...

Descripción completa

Detalles Bibliográficos
Autores principales: Moehler, Markus, Gepfner-Tuma, Irina, Maderer, Annett, Thuss-Patience, Peter C., Ruessel, Joern, Hegewisch-Becker, Susanna, Wilke, Hansjochen, Al-Batran, Salah-Eddin, Rafiyan, Mohammad-Reza, Weißinger, Florian, Schmoll, Hans-Joachim, Kullmann, Frank, von Weikersthal, Ludwig Fischer, Siveke, Jens T., Weusmann, Jens, Kanzler, Stephan, Schimanski, Carl Christoph, Otte, Melanie, Schollenberger, Lukas, Koenig, Jochem, Galle, Peter R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006426/
https://www.ncbi.nlm.nih.gov/pubmed/27582078
http://dx.doi.org/10.1186/s12885-016-2736-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006426/
https://www.ncbi.nlm.nih.gov/pubmed/27582078
http://dx.doi.org/10.1186/s12885-016-2736-9

Ejemplares similares